Vertex (VRTX) Moves Kidney Disease Drug to Phase 3 Development
ZacksVertex (VRTX) advances inaxaplin to late-stage development. It will evaluate the drug in lower age groups and will enroll patients aged 10 years and older with APOL1-mediated kidney disease.